
Imvax Advances a New Approach to Personalized Cancer Immunotherapy
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
BT5K season is here! Join the community and walk or run to make strides against brain tumors!
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
This spring, your gift will be matched dollar for dollar thanks to the generosity of two anonymous donors!